Erasca (ERAS) said Wednesday it has priced an upsized public offering of 22.5 million shares at $10 each.
Gross proceeds are expected to be $225 million, and the offering is expected to close on Friday, the company said.
Erasca said it has also granted underwriters a 30-day option to purchase up to about 3.4 million additional shares.
Erasca said it plans to use net proceeds from the offering to fund research and development and for other general corporate purposes.
Shares of the biotech company were up 1.2% in recent premarket activity Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments